A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer

NCT07649928 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: ES502 Injection

Sponsor

Ruijin Hospital

Collaborators

[object Object]